|
1
|
Molitch ME, DeFronzo RA, Franz MJ, Keane
WF, Mogensen CE, Parving HH and Steffes MW; American Diabetes
Association. Nephropathy in diabetes. Diabetes Care. 27(Suppl 1):
S79–S83. 2004. View Article : Google Scholar
|
|
2
|
Ravid M, Brosh D, Ravid-Safran D, Levy Z
and Rachmani R: Main risk factors for nephropathy in type 2
diabetes mellitus are plasma cholesterol levels, mean blood
pressure, and hyperglycemia. Arch Intern Med. 158:998–1004. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirano T: Lipoprotein abnormalities in
diabetic nephropathy. Kidney Int Suppl. 71:S22–S24. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boyle KE, Phillips MC and Lund-Katz S:
Kinetics and mechanism of exchange of apolipoprotein C-III
molecules from very low density lipoprotein particles. Biochim
Biophys Acta. 1430:302–312. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Breyer ED, Le NA, Li X, Martinson D and
Brown WV: Apolipoprotein C-III displacement of apolipoprotein E
from VLDL: effect of particle size. J Lipid Res. 40:1875–1882.
1999.PubMed/NCBI
|
|
6
|
Jong MC, Hofker MH and Havekes LM: Role of
ApoCs in lipoprotein metabolism: functional differences between
ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 19:472–484.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Campos H, Perlov D, Khoo C and Sacks FM:
Distinct patterns of lipoproteins with apoB defined by presence of
apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
J Lipid Res. 42:1239–1249. 2001.PubMed/NCBI
|
|
8
|
Davidsson P, Hulthe J, Fagerberg B, Olsson
BM, Hallberg C, Dahllöf B and Camejo G: A proteomic study of the
apolipoproteins in LDL subclasses in patients with the metabolic
syndrome and type 2 diabetes. J Lipid Res. 46:1999–2006. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schonfeld G, George PK, Miller J, Reilly P
and Witztum J: Apolipoprotein C-II and C-III levels in
hyperlipoproteinemia. Metabolism. 28:1001–1010. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Talmud PJ and Humphries SE: Apolipoprotein
C-III gene variation and dyslipidaemia. Curr Opin Lipidol.
8:154–158. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sacks FM, Alaupovic P, Moye LA, Cole TG,
Sussex B, Stampfer MJ, Pfeffer MA and Braunwald E: VLDL,
apolipoproteins B, CIII, and E, and risk of recurrent coronary
events in the Cholesterol and Recurrent Events (CARE) trial.
Circulation. 102:1886–1892. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee SJ, Campos H, Moye LA and Sacks FM:
LDL containing apolipoprotein CIII is an independent risk factor
for coronary events in diabetic patients. Arterioscler Thromb Vasc
Biol. 23:853–858. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ginsberg HN, Le NA, Goldberg IJ, Gibson
JC, Rubinstein A, Wang-Iverson P, Norum R and Brown WV:
Apolipoprotein B metabolism in subjects with deficiency of
apolipoproteins CIII and AI. Evidence that apolipoprotein CIII
inhibits catabolism of triglyceride-rich lipoproteins by
lipoprotein lipase in vivo. J Clin Invest. 78:1287–1295. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ebara T, Ramakrishnan R, Steiner G and
Shachter NS: Chylomicronemia due to apolipoprotein CIII
overexpression in apolipoprotein E-null mice. Apolipoprotein
CIII-induced hypertriglyceridemia is not mediated by effects on
apolipoprotein E. J Clin Invest. 99:2672–2681. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sehayek E and Eisenberg S: Mechanisms of
inhibition by apolipoprotein C of apolipoprotein E-dependent
cellular metabolism of human triglyceride-rich lipoproteins through
the low density lipoprotein receptor pathway. J Biol Chem.
266:18259–18267. 1991.PubMed/NCBI
|
|
16
|
Jong MC, Hofker MH and Havekes LM: Role of
ApoCs in lipoprotein metabolism: functional differences between
ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 19:472–484.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shachter NS: Apolipoproteins C-I and C-III
as important modulators of lipoprotein metabolism. Curr Opin
Lipidol. 12:297–304. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le NA, Innis-Whitehouse W, Li X,
Bakker-Arkema R, Black D and Brown WV: Lipid and apolipoprotein
levels and distribution in patients with hypertriglyceridemia:
effect of triglyceride reductions with atorvastatin. Metabolism.
49:167–177. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Friedewald WT, Levy RI and Fredrickson DS:
Estimation of the concentration of low-density lipoprotein
cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem. 18:499–502. 1972.PubMed/NCBI
|
|
20
|
Alberti KG and Zimmet PZ: Definition,
diagnosis and classification of diabetes mellitus and its
complications. Part 1: diagnosis and classification of diabetes
mellitus provisional report of a WHO consultation. Diabet Med.
15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Genuth SM: The case for blood glucose
control. Adv Intern Med. 40:573–623. 1995.PubMed/NCBI
|
|
22
|
Cooper ME: Pathogenesis, prevention, and
treatment of diabetic nephropathy. Lancet. 352:213–219. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brunzell JD and Ayyobi AF: Dyslipidemia in
the metabolic syndrome and type 2 diabetes mellitus. Am J Med.
115(Suppl 8A): S24–S28. 2003. View Article : Google Scholar
|
|
24
|
Batal R, Tremblay M, Barrett PH, Jacques
H, Fredenrich A, Mamer O, Davignon J and Cohn JS: Plasma kinetics
of apoC-III and apoE in normolipidemic and hypertriglyceridemic
subjects. J Lipid Res. 41:706–718. 2000.PubMed/NCBI
|
|
25
|
Barr SI, Kottke BA and Mao SJ:
Postprandial exchange of apolipoprotein C-III between plasma
lipoproteins. Am J Clin Nutr. 34:191–198. 1981.PubMed/NCBI
|
|
26
|
Klein RL, McHenry MB, Lok KH, Hunter SJ,
Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ
and Garvey WT; DCCT/EDIC Research Group. Apolipoprotein C-III
protein concentrations and gene polymorphisms in Type 1 diabetes:
associations with microvascular disease complications in the
DCCT/EDIC cohort. J Diabetes Complications. 19:18–25. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Davidson M: A review of the current status
of the management of mixed dyslipidemia associated with diabetes
mellitus and metabolic syndrome. Am J Cardiol. 102:19L–27L. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takemoto M and Liao JK: Pleiotropic
effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase
inhibitors. Arterioscler Thromb Vasc Biol. 21:1712–1719. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dallongeville J, Fruchart JC, Maigret P,
Bertolini S, Bon GB, Campbell MM, Farnier M, Langan J, Mahla G,
Pauciullo P and Sirtori C: Double-blind comparison of
apolipoprotein and lipoprotein particle lowering effects of
atorvastatin and pravastatin monotherapy in patients with primary
hypercholesterolemia. J Cardiovasc Pharmacol Ther. 3:103–110. 1998.
View Article : Google Scholar
|
|
30
|
Rutter MK, Prais HR, Charlton-Menys V,
Gittins M, Roberts C, Davies RR, Moorhouse A, Jinadev P, France M,
Wiles PG, Gibson JM, Dean J, Kalra PA, Cruickshank JK and
Durrington PN: Protection Against Nephropathy in Diabetes with
Atorvastatin (PANDA): a randomized double-blind placebo-controlled
trial of high- vs. low-dose atorvastatin. Diabet Med. 28:100–108.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Levey AS, Coresh J, Greene T, Marsh J,
Stevens LA, Kusek JW and Van Lente F; Chronic Kidney Disease
Epidemiology Collaboration. Expressing the modification of diet in
renal disease study equation for estimating glomerular filtration
rate with standardized serum creatinine values. Clin Chem.
53:766–772. 2007. View Article : Google Scholar : PubMed/NCBI
|
